Browse

Valneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.

Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.

Moderna announced it will not enroll a new cohort in the phase 3 trial of its mRNA-1403 norovirus vaccine. The decision follows a July interim analysis that showed the vaccine missed its predefine…